ABSTRACT
Sleep recordings were carried out on athletes on four successive nights after completing a 92-kilometer road race. Significant increases in total sleep time and slow-wave sleep were found after this metabolic stress. The results show a definite exercise effect on sleep and support sleep-restoration hypotheses.
Subject(s)
Physical Exertion , Sleep Stages/physiology , Adolescent , Adult , Humans , Running , Sleep, REM/physiologySubject(s)
Catecholamines/therapeutic use , Dobutamine/therapeutic use , Heart Failure/drug therapy , Hemodynamics/drug effects , Myocardium/metabolism , Adult , Aged , Coronary Disease/complications , Coronary Disease/drug therapy , Dose-Response Relationship, Drug , Heart/diagnostic imaging , Heart Failure/complications , Humans , Lactates/metabolism , Male , Middle Aged , Radionuclide ImagingABSTRACT
We assessed the effects of acebutolol, a cardioselective beta blocker, on global and regional left ventricular function in 26 patients with chronic angina pectoris. All patients underwent rest and maximal supine bicycle exercise radionuclide angiography while on placebo and oral acebutolol (400 mg three times a day). Resting ejection fraction on placebo was 51 +/- 3% and on acebutolol was 54 +/- 3% (p less than 0.05). No resting ejection fraction decreased greater than or equal to 7%. Only one patient (resting ejection fraction 28% on placebo and 21% on acebutolol) developed signs of fluid retention. Exercise nuclear studies on placebo revealed responses consistent with coronary artery disease (abnormal ejection fraction response to exercise and regional wall motion abnormalities) in 24 of 26 patients. Peak exercise ejection fraction was of the same order on placebo and acebutolol (51 +/- 3% and 54 +/- 3%, p = NS). In four patients the ejection fraction response to exercise became normal and in five patients all regional wall motion abnormalities became normal on acebutolol. Cardioselective beta blockade with acebutolol in effective antianginal doses is safe and may improve resting and exercise ventricular function.
Subject(s)
Acebutolol/pharmacology , Angina Pectoris/drug therapy , Coronary Disease/drug therapy , Heart/drug effects , Acebutolol/therapeutic use , Blood Pressure/drug effects , Coronary Vessels/diagnostic imaging , Exercise Test , Heart Rate/drug effects , Humans , Male , Radionuclide Imaging , Stroke VolumeSubject(s)
Acebutolol/therapeutic use , Angina Pectoris/drug therapy , Acebutolol/adverse effects , Aged , Angina Pectoris/diagnosis , Blood Pressure/drug effects , Chronic Disease , Double-Blind Method , Drug Evaluation , Exercise Test , Female , Heart Rate/drug effects , Humans , Male , Middle Aged , Nitroglycerin/therapeutic use , PlacebosABSTRACT
We have investigated the effect of ascorbic acid (vitamin C) supplementation on some parameters of the human immune defence system in a group of 25 healthy, male university students. The subjects ingested 1 g ascorbic acid per day for a period of 75 days. Serum levels of IgA, IgG, IgM, C-3 complement component, cortisol and transcortin were measured before and after the ascorbic acid course. Corresponding measurements were performed on a control group of 20 healthy, male university students receiving no extra-dietary vitamin C. Our results showed that ascorbic acid supplementation caused a statistically significant increase in the serum levels of IgA, IgM and C-3 complement. Our study does not permit of conclusions regarding the mechanisms of action of ascorbic acid.
